TCL Archive New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial May 30, 2014
TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive In Brief: Griesemer Returns To NIEHS to Head Toxicology Research & Testing; Robert Burnight Dies at 69 August 12, 1988
TCL Archive NCI, FDA Make Progress On Some Issues, Bu Differences Remain On Endpoints November 10, 1989
